Atlas Trials

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

Clinical trial NCT03856099 · TERMINATED

Trial details

NCT number
NCT03856099
Sponsor
PharmAbcine
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Glioblastoma
Start date
2019-11-13
Primary completion
2022-07-15
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.